Association of mannose-binding lectin-2 gene polymorphism with the development of hepatitis C-induced hepatocellular carcinoma

Liver International

Volumn 31, Issue 7, 2011, Pages 1006-1012

  Eurich, Dennis ^a   Boas Knoop, Sabine ^a   Morawietz, Lars ^b   Neuhaus, Ruth ^a   Somasundaram, Rajan ^c   Ruehl, Martin ^c   Neumann, Ulf P ^a   Neuhaus, Peter ^a   Bahra, Marcus ^a   Seehofer, Daniel ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Genetic variants; HCC; HCV; Liver explants; MBL 2

Indexed keywords

ALPHA FETOPROTEIN; MANNOSE BINDING LECTIN 2;

ADULT; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; TUMOR VOLUME;

AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; DNA PRIMERS; FEMALE; GENOTYPE; GERMANY; HEPATITIS C; HUMANS; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MANNOSE-BINDING LECTIN; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 79960088594     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02522.x     Document Type: Article

References (36)

1. Rossol S. Chronic HCV infections. A model disease for therapy, economics and social-medical aspects. Gesundheitswesen 2007; 69: 146-50.
2. Iadonato SP, Katze MG. Genomics: hepatitis C virus gets personal. Nature 2009; 461: 357-8.
3. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003; 22: 5093-107.
4. Neumann UP, Berg T, Bahra M, et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004; 77: 226-31.
5. Schuppan D, Krebs A, Bauer M, Hahn EG. Hepatitis C and liver fibrosis. Cell Death Differ 2003; 10 (Suppl. 1): S59-67.
6. Ben-Ari Z. Role of cytokine gene polymorphism in recurrent HCV infection after liver transplantation. Liver Transpl 2006; 12: 1723-4.
7. Powell EE, Edwards-Smith CJ, Hay JL, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000; 31: 828-33.
8. Bidwell JL, Wood NA, Morse HR, Olomolaiye OO, Laundy GJ. Human cytokine gene nucleotide sequence alignments, 1998. Eur J Immunogenet 1998; 25: 83-265.
9. Segat L, Fabris A, Padovan L, et al. MBL2 and MASP2 gene polymorphisms in patients with hepatocellular carcinoma. J Viral Hepat 2008; 15: 387-91.
10. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-18.
11. Wasmuth HE, Werth A, Mueller T, et al. CC chemokine receptor 5 delta32 polymorphism in two independent cohorts of hepatitis C virus infected patients without hemophilia. J Mol Med 2004; 82: 64-9.
12. Larsen F, Madsen HO, Sim RB, Koch C, Garred P. Disease-associated mutations in human mannose-binding lectin compromise oligomerization and activity of the final protein. J Biol Chem 2004; 279: 21302-11.
13. Butler GS, Sim D, Tam E, Devine D, Overall CM. Mannose-binding lectin (MBL) mutants are susceptible to matrix metalloproteinase proteolysis: potential role in human MBL deficiency. J Biol Chem 2002; 277: 17511-9.
14. Crosdale DJ, Ollier WE, Thomson W, et al. Mannose binding lectin (MBL) genotype distributions with relation to serum levels in UK Caucasoids. Eur J Immunogenet 2000; 27: 111-7.
15. Madsen HO, Garred P, Thiel S, et al. Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol 1995; 155: 3013-20.
16. Sasaki K, Tsutsumi A, Wakamiya N, et al. Mannose-binding lectin polymorphisms in patients with hepatitis C virus infection. Scand J Gastroenterol 2000; 35: 960-5.
17. Matsushita M, Hijikata M, Ohta Y, et al. Hepatitis C virus infection and mutations of mannose-binding lectin gene MBL. Arch Virol 1998; 143: 645-51.
18. Fildes JE, Shaw SM, Walker AH, et al. Mannose-binding lectin deficiency offers protection from acute graft rejection after heart transplantation. J Heart Lung Transplant 2008; 27: 1353-6.
19. Gremion C, Cerny A. Hepatitis C virus and the immune system: a concise review. Rev Med Virol 2005; 15: 235-68.
20. Steffensen R, Thiel S, Varming K, Jersild C, Jensenius JC. Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers. J Immunol Methods 2000; 241: 33-42.
21. Rantala A, Lajunen T, Juvonen R, et al. Mannose-binding lectin concentrations, MBL2 polymorphisms, and susceptibility to respiratory tract infections in young men. J Infect Dis 2008; 198: 1247-53.
22. Cervera C, Balderramo D, Suarez B, et al. Donor mannose-binding lectin gene polymorphisms influence the outcome of liver transplantation. Liver Transpl 2009; 15: 1217-24.
23. Worthley DL, Johnson DF, Eisen DP, et al. Donor mannose-binding lectin deficiency increases the likelihood of clinically significant infection after liver transplantation. Clin Infect Dis 2009; 48: 410-7.
24. Ben-Ari Z, Pappo O, Druzd T, et al. Role of cytokine gene polymorphism and hepatic transforming growth factor beta1 expression in recurrent hepatitis C after liver transplantation. Cytokine 2004; 27: 7-14.
25. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
26. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
27. Halla MC, do Carmo RF, Silva Vasconcelos LR, et al. Association of hepatitis C virus infection and liver fibrosis severity with the variants alleles of MBL2 gene in a Brazilian population. Hum Immunol 2010; 71: 883-7.
28. Baccarelli A, Hou L, Chen J, et al. Mannose-binding lectin-2 genetic variation and stomach cancer risk. Int J Cancer 2006; 119: 1970-5.
29. Bataller R. Genetic polymorphisms and liver diseases. Gastroenterol Hepatol 2003; 26: 307-9.
30. Kilpatrick DC, Delahooke TE, Koch C, Turner ML, Hayes PC. Mannan-binding lectin and hepatitis C infection. Clin Exp Immunol 2003; 132: 92-5.
31. Brown KS, Ryder SD, Irving WL, Sim RB, Hickling TP. Mannan binding lectin and viral hepatitis. Immunol Lett 2007; 108: 34-44.
32. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
33. Berenguer M. Recurrent allograft disease: viral hepatitis. Acta Gastroenterol Belg 2005; 68: 337-46.
34. Neumann U, Puhl G, Bahra M, et al. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin. Transplantation 2006; 82: 43-7.
35. Eurich D, Bahra M, Boas-Knoop S, et al. Transforming growth factor β-1 polymorphisms and graft fibrosis progression after liver transplantation for HCV-induced liver disease. Liver Transpl 2010; 17: 279-88.
36. Eurich D, Boas-Knoop S, Ruehl M, et al. Association of IL-28b gene polymorphism to histological severity of HCV-induced graft inflammation and response to antiviral therapy. Liver Transpl 2010; 17: 289-98.